Table 1 Overview of all cases analyzed and entity specific alterations with frequencies
Entity | # | Aberrations | # | Frequency |
|---|---|---|---|---|
Astrocytic glioma, IDH-mutant (WHO grade II/III/IV) | 19 | IDH1/2 | 19 | 100% |
TP53 | 18 | 95% | ||
ATRX | 7 | 37% | ||
CDKN2A HomDel | 2 | 11% | ||
Oligodendroglioma, IDH-mutant 1p/19q-codeleted (WHO grade II/III) | 14 | IDH1/2 | 14 | 100% |
1p/19q LOH | 14 | 100% | ||
TERTp | 14 | 100% | ||
CIC | 11 | 79% | ||
FUBP1 | 4 | 29% | ||
Astrocytic glioma, IDH-wildtype (WHO grade I/II/III/IV) | 42 | TERTp | 30 | 71% |
10 DEL / 7 AMP | 14 | 33% | ||
EGFR Highcopy | 9 | 21% | ||
TP53 | 9 | 21% | ||
NF1 | 5 | 12% | ||
BRAF | 4 | 10% | ||
Diffuse midline glioma, H3K27M-mutant (WHO grade IV) | 2 | H3F3A | 2 | 100% |
TP53 | 2 | 100% | ||
Meningioma (WHO grade I/II/III) | 19 | NF2 | 15 | 79% |
SMARCB1 | 15 | 79% | ||
1p DEL | 12 | 63% | ||
CDKN2A HomDel | 4 | 21% | ||
TERTp | 0 | 0% | ||
Medulloblastoma (WHO grade IV) | 8 | TERTp | 3 | 38% |
TP53 | 2 | 25% | ||
OTX2 Highcopy | 1 | 13% | ||
CTNNB1 | 1 | 13% | ||
Monosomy 6 | 1 | 13% | ||
Isochromosome 17 | 1 | 13% |